These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 34053678)

  • 1. Higher risk of type 2 diabetes in women with hyperandrogenic polycystic ovary syndrome.
    Persson S; Elenis E; Turkmen S; Kramer MS; Yong EL; Poromaa IS
    Fertil Steril; 2021 Sep; 116(3):862-871. PubMed ID: 34053678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective risk of Type 2 diabetes in 99 892 Nordic women with polycystic ovary syndrome and 446 055 controls: national cohort study from Denmark, Finland, and Sweden.
    Glintborg D; Ollila MM; Møller JK; Pesonen P; Persson S; Elenis E; Rubin KH; Gissler M; Andersen MS; Sundström-Poromaa I; Piltonen T
    Hum Reprod; 2024 Aug; 39(8):1823-1834. PubMed ID: 38859639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early initiation of anti-androgen treatment is associated with increased probability of spontaneous conception leading to childbirth in women with polycystic ovary syndrome: a population-based multiregistry cohort study in Sweden.
    Elenis E; Desroziers E; Persson S; Sundström Poromaa I; Campbell RE
    Hum Reprod; 2021 Apr; 36(5):1427-1435. PubMed ID: 33454768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life.
    Pinola P; Puukka K; Piltonen TT; Puurunen J; Vanky E; Sundström-Poromaa I; Stener-Victorin E; Lindén Hirschberg A; Ravn P; Skovsager Andersen M; Glintborg D; Mellembakken JR; Ruokonen A; Tapanainen JS; Morin-Papunen LC
    Fertil Steril; 2017 Mar; 107(3):788-795.e2. PubMed ID: 28089571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Risk Factors of Type 2 Diabetes in a Nationwide Population of Women With Polycystic Ovary Syndrome.
    Rubin KH; Glintborg D; Nybo M; Abrahamsen B; Andersen M
    J Clin Endocrinol Metab; 2017 Oct; 102(10):3848-3857. PubMed ID: 28938447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of type 2 diabetes is increased in nonobese women with polycystic ovary syndrome: the National Health Insurance Service-National Sample Cohort Study.
    Ryu KJ; Kim MS; Kim HK; Kim YJ; Yi KW; Shin JH; Hur JY; Kim T; Park H
    Fertil Steril; 2021 Jun; 115(6):1569-1575. PubMed ID: 33509630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased rates of complications in singleton pregnancies of women previously diagnosed with polycystic ovary syndrome predominantly in the hyperandrogenic phenotype.
    de Wilde MA; Lamain-de Ruiter M; Veltman-Verhulst SM; Kwee A; Laven JS; Lambalk CB; Eijkemans MJC; Franx A; Fauser BCJM; Koster MPH
    Fertil Steril; 2017 Aug; 108(2):333-340. PubMed ID: 28778282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of type 2 diabetes in adolescent girls with polycystic ovary syndrome and obesity.
    Hudnut-Beumler J; Kaar JL; Taylor A; Kelsey MM; Nadeau KJ; Zeitler P; Snell-Bergeon J; Pyle L; Cree-Green M
    Pediatr Diabetes; 2021 Aug; 22(5):699-706. PubMed ID: 33870630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperandrogenism and phenotypes of polycystic ovary syndrome are not associated with differences in obstetric outcomes.
    Mumm H; Jensen DM; Sørensen JA; Andersen LL; Ravn P; Andersen M; Glintborg D
    Acta Obstet Gynecol Scand; 2015 Feb; 94(2):204-11. PubMed ID: 25417943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance.
    Jones H; Sprung VS; Pugh CJ; Daousi C; Irwin A; Aziz N; Adams VL; Thomas EL; Bell JD; Kemp GJ; Cuthbertson DJ
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3709-16. PubMed ID: 22837189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomere Length Differently Associated to Obesity and Hyperandrogenism in Women With Polycystic Ovary Syndrome.
    Velazquez ME; Millan AL; Rojo M; Abruzzese GA; Cocucci SE; Iglesias Molli AE; Frechtel GD; Motta AB; Cerrone GE
    Front Endocrinol (Lausanne); 2021; 12():604215. PubMed ID: 34054718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polycystic ovary syndrome and risk of pre-eclampsia: A national register-based cohort study.
    Valdimarsdottir R; Vanky E; Elenis E; Lindström L; Junus K; Jonsson M; Sundström Poromaa I; Wikström AK
    BJOG; 2024 Jun; 131(7):985-995. PubMed ID: 38082470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome.
    Glintborg D; Rubin KH; Nybo M; Abrahamsen B; Andersen M
    Cardiovasc Diabetol; 2018 Mar; 17(1):37. PubMed ID: 29519249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of polycystic ovary syndrome or anovulatory infertility with offspring psychiatric and mild neurodevelopmental disorders: a Finnish population-based cohort study.
    Chen X; Kong L; Piltonen TT; Gissler M; Lavebratt C
    Hum Reprod; 2020 Oct; 35(10):2336-2347. PubMed ID: 32866965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of biochemical hyperandrogenism with type 2 diabetes and obesity in Chinese women with polycystic ovary syndrome.
    Zhao X; Zhong J; Mo Y; Chen X; Chen Y; Yang D
    Int J Gynaecol Obstet; 2010 Feb; 108(2):148-51. PubMed ID: 19932893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycystic ovary syndrome is not associated with genetic variants that mark risk of type 2 diabetes.
    Saxena R; Welt CK
    Acta Diabetol; 2013 Jun; 50(3):451-7. PubMed ID: 22389004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal difference in phenotype between adolescents and young adults with polycystic ovary syndrome.
    Zore T; Lizneva D; Brakta S; Walker W; Suturina L; Azziz R
    Fertil Steril; 2019 Feb; 111(2):389-396. PubMed ID: 30527835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased risk of preterm delivery and pre-eclampsia in women with polycystic ovary syndrome and hyperandrogenaemia.
    Naver KV; Grinsted J; Larsen SO; Hedley PL; Jørgensen FS; Christiansen M; Nilas L
    BJOG; 2014 Apr; 121(5):575-81. PubMed ID: 24418062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of hyperandrogenism on obstetric complications of singleton pregnancy from in vitro fertilization in women with polycystic ovary syndrome].
    Wei DM; Zhang ZZ; Wang Z; Li P; Wang JF; Liu YJ; Zhang JT; Shi YH
    Zhonghua Fu Chan Ke Za Zhi; 2018 Jan; 53(1):18-22. PubMed ID: 29374881
    [No Abstract]   [Full Text] [Related]  

  • 20. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2.
    Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
    Endocr Pract; 2015 Dec; 21(12):1415-26. PubMed ID: 26642102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.